ImmunoGen, Inc. (IMGN) earnings
Quarterly and annual IMGN reports and results, each read against the price at its own news timestamp. Back to the IMGN overview →
3 measured IMGN earnings events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q ImmunoGen, Inc. For: Sep 30 | SEC filing · Form 10-Q | -3.09% | +2.71% | |
| ImmunoGen Reports Recent Progress and Third Quarter 2023 Financial Results | Press release | +2.17% | -1.27% | |
| ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2023 Operating Results | Press release | -1.43% | -3.94% |
Keep exploring
More IMGN: analyst actions → · SEC filings → · IMGN overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| InflaRx N.V. (IFRX) | 142 | 0.00% | 48% |
| Oncocyte Corporation (OCX) | 141 | 0.00% | 47% |
| MEDIFIRST SOLUTIONS (MFST) | 140 | 0.00% | 47% |
| Pro-Dex, Inc. (PDEX) | 140 | 0.00% | 45% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.